NNG
NANOGROUP
GPW
LISTED
source: current reports (ESPI/EBI) · incomplete data — not every contract is disclosed · 8 contracts in the database
DISCLOSED VALUE 12M
Sum of the value of contracts from the last 12 months where the company disclosed an amount; contracts with no disclosed value are excluded.
292 m PLN
3 of 7 contracts
+3 in another currency, excluded from the total
SHARE OF REVENUE 12M
Disclosed contract value relative to the company's revenue; computed only when both figures are in PLN.
—
no revenue data in the database
LARGEST COUNTERPARTY
61.3%
Auxilius Pharma S.A.
LONGEST TERM
6 months
until 2027
No contracts in this category.
The registry is built from significant-contract announcements — none of this company's contracts carries the selected status.
Counterparty concentration
share of disclosed contract value over the last 12 months
Auxilius Pharma S.A.
61.3%
AUXILIUS PHARMA S.A., założyciele AUX (Jędrzej Litwiniuk, Uwe Tigör), FF VENTURE CAPITAL sp. z o.o., prof. Tomasz Ciach, akcjonariusze NanoGroup (ECAPITAL sp. z o.o., Fundacja Rodziny Wesołowskich, Robert Dziubłowski, 5M Square sp. z o.o., R_D Property sp. z o.o., Top Consulting S.A., Falasarna S...
37.4%
SyVento Sp. z o.o.
1.3%
Portfolio summary
Contracts
8
Active
8
Total value
292 m PLN
Average value
97.4 m PLN
Since
January 30, 2026
Where this data comes from
Contracts come from current reports (ESPI/EBI) — the company discloses only those exceeding its materiality threshold. The list is by definition incomplete.
Status — inferred from the event type and the term's end date, not a dedicated source field.
Share of revenue 12M — only when both the contracts' dominant currency and the company's reporting currency are PLN, with no currency conversion.